174 related articles for article (PubMed ID: 12232491)
1. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.
Stauder H; Kreuser ED
Onkologie; 2002 Aug; 25(4):374-80. PubMed ID: 12232491
[TBL] [Abstract][Full Text] [Related]
2. [Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
Mengs U; Witthohn K; Schwarz T; Lentzen H
Wien Med Wochenschr; 1999; 149(8-10):262-4. PubMed ID: 10483695
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire.
Kirchberger I; Wetzel D; Finger T
Qual Life Res; 2004 Mar; 13(2):463-79. PubMed ID: 15085919
[TBL] [Abstract][Full Text] [Related]
4. [Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius S; Gabius HJ
Dtsch Med Wochenschr; 2002 Mar; 127(9):457-9. PubMed ID: 11870561
[No Abstract] [Full Text] [Related]
5. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study.
Huber R; Lüdtke R; Klassen M; Müller-Buscher G; Wolff-Vorbeck G; Scheer R
Eur J Med Res; 2001 Sep; 6(9):399-405. PubMed ID: 11669085
[TBL] [Abstract][Full Text] [Related]
6. [The mistletoe myth--claims, reality and provable perspectives].
Gabius HJ; André S; Kaltner H; Siebert HC; von der Lieth CW; Gabius S
Z Arztl Fortbild (Jena); 1996 Apr; 90(2):103-10. PubMed ID: 8686332
[TBL] [Abstract][Full Text] [Related]
7. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.
Mengs U; Göthel D; Leng-Peschlow E
Anticancer Res; 2002; 22(3):1399-407. PubMed ID: 12168816
[TBL] [Abstract][Full Text] [Related]
8. Evaluating unconventional therapies.
Hajto T; Saller R
CMAJ; 1998 Oct; 159(7):759; author reply 759, 761. PubMed ID: 9805018
[No Abstract] [Full Text] [Related]
9. Clinical relevance of immunoactive mistletoe lectin-I.
Beuth J
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
11. Mistletoe compound enters clinical trials.
Habeck M
Drug Discov Today; 2003 Jan; 8(2):52-3. PubMed ID: 12565000
[TBL] [Abstract][Full Text] [Related]
12. Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.
Klein R; Classen K; Fischer S; Errenst M; Scheffler A; Stein GM; Scheer R; von Laue HB
Eur J Med Res; 2002 Aug; 7(8):359-67. PubMed ID: 12204844
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract][Full Text] [Related]
14. [Comment on S. Gabius, H.-J. Gabius: Immune modulating mistletoe therapy by lectin standardization: a double-edged sword?].
Wetzel D; Mengs U; Schwarz T
Versicherungsmedizin; 2000 Mar; 52(1):38-40. PubMed ID: 10718092
[No Abstract] [Full Text] [Related]
15. [Mistletoe therapy from the pharmacologic perspective].
Hajto T; Hostanska K; Saller R
Forsch Komplementarmed; 1999 Aug; 6(4):186-94. PubMed ID: 10529578
[TBL] [Abstract][Full Text] [Related]
16. Mistletoe or not mistletoe is still the question.
Kiene H; Büschel G; Hornebar M
Forsch Komplementarmed Klass Naturheilkd; 2001 Oct; 8(5):309-12. PubMed ID: 11760713
[No Abstract] [Full Text] [Related]
17. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
Piao BK; Wang YX; Xie GR; Mansmann U; Matthes H; Beuth J; Lin HS
Anticancer Res; 2004; 24(1):303-9. PubMed ID: 15015612
[TBL] [Abstract][Full Text] [Related]
18. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
[TBL] [Abstract][Full Text] [Related]
19. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review.
Bocci V
J Biol Regul Homeost Agents; 1993; 7(1):1-6. PubMed ID: 8346712
[TBL] [Abstract][Full Text] [Related]
20. [Ingredients of mistletoe (Viscum album L.) as potential drugs].
Franz H
Pharmazie; 1985 Feb; 40(2):97-104. PubMed ID: 3889937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
